Completed PHASE1 INTERVENTIONAL 2-arm NCT01611428

Absolute Bioavailability Study With Ipragliflozin

A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin

Sponsor: Astellas Pharma Europe B.V.

Conditions Bioavailability of Ipragliflozin Healthy Subjects

Interventions Ipragliflozin

Updated 5 times since 2017 Last updated: May 31, 2012 Started: Jun 30, 2011 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01611428, this PHASE1 trial focuses on Bioavailability of Ipragliflozin and Healthy Subjects and remains completed. Sponsored by Astellas Pharma Europe B.V., it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2017 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Europe B.V.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom